ImmunoCellular Therapeutics at World Cancer Vaccines Summit (6/23/11, Boston)
 

http://www.marketwatch.com/story/imm...k=MW_news_stmp

The data shows 6 out of the 16 (37.6%) newly diagnosed patients who received ICT-107 continue to show no tumor recurrence, with 3 of these patients (18.8%) remaining disease-free for almost four years while the other 3 patients have gone more than 2 and a half years disease-free. No treatment related serious adverse events have been observed to date.